Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2026-07-06 17:02:06 ET · period of report 2026-07-01 · accession 0002019493-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-06 17:02 | 2026-07-01 | NTLA | Dube Michael P | VP, CAO | S - Sale | $16.78 | -2,641 | 66.9K | -4% | -$44.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-01 | S | D | 2,641 | $16.78 | 66,886 | D | — | — | (F1) Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on July 1, 2026, and does not represent a volitional trade by the Reporting Person. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.78 to $17.12, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2026 at each separate price. |